News | Left Atrial Appendage (LAA) Occluders | October 28, 2015

SentreHeart Receives CE Mark for Lariat Suture Delivery Device

Device gives European surgeons a new option for soft tissue closure, including the left atrial appendage

Sentreheart, Lariat Surgical LAA Suture Delivery Device, left atrial appendage closure, CE Mark approval, Europe

Image courtesy of SentreHeart

October 28, 2015 — SentreHeart Inc. announced that it has received CE Mark approval for the Lariat Surgical Left Atrial Appendage (LAA) Suture Delivery Device. The Lariat Surgical LAA device is a suture-based solution for soft tissue closure, including the LAA. European surgeons can now offer their patients precise, user-controlled delivery of a 50mm pre-tied suture loop through traditional open surgical procedures or through an access port as small as 5mm.

The device compliments the company’s innovative soft tissue closure technology by leveraging the Lariat’s low-profile delivery, designed to be compatible with a broad array of surgical approaches for LAA or other soft tissue closure. Features of the Lariat include an easy-to-use 50mm snare that is compatible with access as small as 5mm, a malleable shaft design for ease of use in delivery from different access locations and an integrated suture-tightening system to reduce the risk of operator variability during closure. The surgeon, while under direct visualization, can guide the snare loop over soft tissue, including the left atrial appendage, confirm its exact closure location and deploy the pre-tied suture, resulting in immediate, complete ligation without leaving any metal or clip behind.

Unlike current surgical closure solutions, including staplers and clips, the Lariat Surgical LAA device uses a common polyester suture, which may prevent any metal-to-tissue interaction. Additionally, its low-profile design will give surgeons greater control in suture placement location and is designed to be compatible with open-chest, thoracotomy or port access procedures.

Krzysztof Bartus, M.D., Ph.D., associate professor of cardiac surgery at Jagiellonian University Krakow, Poland stated, “The Lariat Surgical device is an elegant surgical closure solution, combining the best of all the current approaches into a single device. The new device enables flexibility in my approach and access to close tissue where I want, with the additional confidence that it will remain closed. These are important characteristics when closing soft tissue such as the left atrial appendage.”

For more information: www.sentreheart.com

Related Content

The Boston Scientific Watchman device have performed better than expected in real-world patients outside of trials since it was introduced in 2015, according to data from the NCDR LAAO Registry. #ACC21 #ACC2021 #LAA #Watchman

The Boston Scientific Watchman device have performed better than expected in real-world patients outside of trials since it was introduced in 2015, according to data from the NCDR LAAO Registry.

Feature | Left Atrial Appendage (LAA) Occluders | May 16, 2021
May 15, 2021 - Transcatheter...
In the LAAOS III trial, surgeons could seal off the LAA during the open heart procedure using sutures, staples or approved closure devices. The image shows a SentraHeart lasso type LAA occluder about to seal off the LAA from the outside of the heart.  #ACC21 #ACC2021

In the LAAOS III trial, surgeons could seal off the LAA during the open heart procedure using sutures, staples or approved closure devices. The image shows a SentraHeart lasso type LAA occluder about to seal off the LAA from the outside of the heart. 

News | Left Atrial Appendage (LAA) Occluders | May 15, 2021
May 15, 2021 — Patients with an elevated risk of stroke due to heart rhythm problems, or...
Positive clinical data from first-in-human studies of the Conformal Medical left atrial appendage closure (LAAC) CLAAS device performed in the U.S. and Prague were presented at 2020 Transcatheter Cardiovascular Therapeutics (TCT) Connect virtual meeting. Two two abstracts were presented by William Gray, M.D., from Lankenau Heart Institute, Wynnewood, Penn., and Vivek Reddy, M.D., from Mount Sinai Hospital in New York. #TCT2020 #TCTconnect
News | Left Atrial Appendage (LAA) Occluders | October 16, 2020
October 16, 2020 — Positive clinical data from first-in-human studies of the Conformal Medical...
Boston Scientific recently introduced the newst iteration of LAA occluder device, the Watchman FLX. It uses small spikes to help better anchor the device and prevent embolization.

Boston Scientific recently introduced the newst iteration of LAA occluder device, the Watchman FLX. It uses small spikes to help better anchor the device and prevent embolization. Read more on this FDA approval.

News | Left Atrial Appendage (LAA) Occluders | August 21, 2020
August 21, 2020 — According to a report published by Research Dive, the rising number of patients suffering from...
The Conformal Medical CLAAS device, a next-generation transcatheter left atrial appendage (LAA) closure occluder for patients with atrial fibrillation (AF). LAA occlusion allows AFib patients to go off of life-long anticoagulation therapy. #LAA #LAAC

The Conformal Medical CLAAS device, a next-generation transcatheter left atrial appendage (LAA) closure occluder for patients with atrial fibrillation (AF). LAA occlusion allows AFib patients to go off of life-long anticoagulation therapy.

News | Left Atrial Appendage (LAA) Occluders | August 06, 2020
August 6, 2020 – Conformal Medical Inc.
Append Medical, developer of a novel left atrial appendage (LAA) closure device to minimize stroke risk in atrial fibrillation (AF) patients, announced that it has been selected from among hundreds of startups as a finalist for the ICI Innovation Award Competition. It uses a transcatheter lasso system so no implant is left behind and eliminates the possibility of embolization.

Append Medical, developer of a novel left atrial appendage (LAA) closure device to minimize stroke risk in atrial fibrillation (AF) patients, announced that it has been selected from among hundreds of startups as a finalist for the ICI Innovation Award Competition. It uses a transcatheter lasso system so no implant is left behind and eliminates the possibility of embolization.

News | Left Atrial Appendage (LAA) Occluders | December 18, 2019
December 18, 2019 — Append Medical, developer of a novel left atrial app